Carbonic Anhydrase Activators. Part 191 Spectroscopic and Kinetic Investigations for the Interaction of Isozymes I and II With Primary Amines by Briganti, Fabrizio et al.
CARBONIC ANHYDRASE ACTIVATORS. PART 19
SPECTROSCOPIC AND KINETIC INVESTIGATIONS FOR THE
INTERACTION OF ISOZYMES AND II WITH PRIMARY AMINES
Fabrizio Briganti, Andrea Scozzafava and Claudiu T. Supuran*
Universit& degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica,
Via Gino Capponi 7, 1-50121 Firenze, Italy.
Abstract: The interactions ofZn(II)- and Co(II)-substituted carbonic anhydrase (CA) isozymes and II with
amine type activators such as histamine, serotonin, phenetylamine dopamine and benzylhydrazine have been
investigated kinetically, and spectroscopically. All of such activators are of the non-competitive type towards
CO2 hydration and 4-nitrophenylacetate hydrolysis for both human isozymes (HCA and HCA II). The
electronic spectra of the adducts of Co(II)CA with amine activators are similar to the spectrum of the
previously reported Co(II)CAII-phenol adduct, the only known competitive inhibitor towards CO2 hydration,
where the phenol molecule binds into the hydrophobic pocket of the active site. This is a direct spectroscopic
evidence that the activator molecules bind within the active site, but not directly to the metal ion. Recent X-
ray crystallographic data for the adduct ofHCA II with histamine show that the activator molecule is bound
at the entrance of the active site cavity, near to residues His 64, Asn 62 and Gln 92, where actively aids in
shuttling protons between the active site and the environment. Similar arrangements probably occur for the
other activators reported in the present paper.
Introduction
Carbonic anhydrase (CA, EC 4.2.1.1), a zinc enzyme widely spread in the bacterial, vegetal and
animal kingdoms,
2’3 catalyzes one of the simplest physiological reactions, the reversible interconversion
between CO2 and the bicarbonate ion.
36 Although at least eight distinct isozymes (CA I-VIII)are presently
known in higher vertebrates, together with two CA-like proteins (CA IX and CA X), the physiological
function for many ofthem is still unknown;
Activatorslf isomes HCA and II possessing the general f.ormula 1 (ArCH(R3)CH(R2)NHR (R
H, OH, COOH; R =H, Me) have recently been described,
8Iv and kinetic measurements were done
both for the hydrase
t as well as esterase activity, proving a non-competitive type of interaction.: It is
generally assumed that activators facilitate the rate-determining step in catalysis, which is a proton transfer
reaction, delineated below by equations 2 and 3.
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The above mechanism proposed earlier by one of us, has recently been confirmed after the report of
the X-ray crystallographic structure of the adduct of histamine, an effectiveCA activator, with HCA II
3 as
well as that of the ternary complex of HCA II with phenylalanine and azide. As seen from Fig. 1, the
activator molecule is bound at the entrance of the active site cavity in a region rich in hydrophilic amino acid
residues, having a suitable orientation for shuttling protons between the active site and the environment.
Taking into account the fact that biologically relevant molecules possessing the general formula 1,
others than histamine 2, such as serotonin 3, dopamine 4, or phenethylamine 5 (the simplest compound
12" possessing formula 1) have been previously shown to activate differentCA isozymes, it appeared of
interest to undergo a detailed study regarding their interaction with native and metallo-substituted CAs, in
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Fig. 1" HCA II- histamine adduct. The Zn(II)ion (central sphere)and its three histidine ligands (His 94,
His 96 and His 119), as well as active site residues involved in histamine binding (named HST 264) such as
His 64, Ash 62 and Gin 92, are evidenced. The figure was generated by using the program RasWin from the
X-ray crystallographic coordinates of Briganti et al (Brookhaven Protein Database accession No. 4TST).
3
order to verify whether their mechanism of action is similar to the one described above for histamine
binding.
3 In his paper we report kinetic and spectroscopic studies regarding the interaction of four such





4: R = OH; X C1-!2
5: R = H; X C1"12
6: R = H; X NH
Human CA and CA II cDNAs were expressed in Ion Escherichia coli strain BL21 (DE3) from the
plasmids pACA/HCA and pACA/HCA II
4 (the two plasmids were a gift from Prof. Sven Lindskog, Umea
University, Sweden). Cell growth conditions were those described by Lindskoz’s group,
5 and enzymes were
purified by affinity chromatography according to the method of Khalifah et al." Enzyme concentrations were
determined spectrophotometrically at 280 nm, utilizing a molar absorptivity of49 mM .cm" for CA and
54 mM-.cm- for CA II, respectively, based on Mr 28.85 kDa for CA I, and 29.3 kDa for CA II,
17 18 respectively. Apoenzymes were prepared by dialysing the zinc enzymes against 50 mM pyridine-2,6-
2 hours. The chelating agent was removed dicarboxylic acid (Sigma) in 0.2 M phosphate buffer at 4C for
r9
by dialysis against 20 mM Tris-H2SO4 (pH 7.5) and then 1.1 equivalents of CoSO4 were added to the
apoenzymes in order to obtain Co(II)CAs. Activators (compounds 2-6), 4-nitrophenyl acetate and solvents
were from Sigma or Acros and were used without further purification.
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Electronic spectra were recorded with a Cary 3 spectrophotometer interfaced with an IBM PC. Initial
rates of 4-nitrophenyl acetate hydrolysis were monitored spectrophotometrically, at 400 nm and 25C, with a
Cary 3 apparatus interfaced with an IBM compatible PC. Solutions of substrate were prepared in anhydrous
acetonitrile; the substrate concentrations varied between 10z and 10
.5 M. A molar absorption coefficiente
18400 M.cm was used for the 4-nitrophenolate formed by hydrolysis, in the conditions of the experiments
(pH 7.80), as reported by Pocker and Stone.
2 Non-enzymatic hydrolysis rates were always subtracted from
the observed rates. Stock solutions of activators (10 raM) were prepared in DMSO and dilutions up to 0.01
M were done with distilled deionized water. Duplicate experiments were done for each activator, and the
values reported throughout the paper are the averages of such results. Hdratase activity in the absence and in
the presence ofactivators has been measured by Maren’s micromethod at 0C. Water saturated with 100%
CO2 (at 0C) has been used as substrate. Stock solutions of activators (1 mM) were prepared in distilled-
deionized water with 10-20% (v/v) DMSO for compounds possessing poor water solubility (DMSO is not
inhibitory/activatory at the concentrations used in these experiments) and dilutions up to 0.01 tM were done
thereafterwith distilled-deionized water. Activator and enzyme solutions were preincubated together for 10
min. at room temperature prior to assay, in order to allow for the formation of the E-A complex. In a special
CO2 bubbler cell 0.3 mL of distilled water was added, followed by 0.4 mL of phenol red indicator solution
(1%) and (0.1 mL of inhibitor + 0.1 mL of CA solution, preincubated as mentioned above). The CA
concentrations were 1.5 nM for CA II, 14 nM for CA I. The hydration reaction was initiated by addition of
0.1 mL of barbital buffer (pH 7.5), and the time to obtain a color change has been recorded with a stopwatch.
Enzyme specific activity in the presence and in the absence of activators was determined as described by
Maren.
21 The standard error ofthese measurements is around 5-10 %.
21
Results and Discussion
Activation ofthe hydrase as well as esterase activity ofHCA and II with derivatives 2-6 is shown
in table I, at concentrations of 10M of activator.
Table I. HCA and II activation with compounds 2-6 at concentrations of 10 laM, for 4-nitrophenyl acetate
hydrolysis (4-NPA) and CO2 hydration reactions.
Activator % CA activity
4-NPA hydrolysisb CO2 hydrationC
HCA HCA II HCA HCA II
2 161 119 176 150
3 118 108 143 112
4 123 110 159 138
5 112 106 115 109
6 114 108 117 108
CA activity in the absence of activator is taken as 100%; At 25 C; At 0 C.
As seen from data of Table I, the most potent activator in this series is histamine 2, followed by
dopamine 4 and serotonin 3, whereas phenethylamine 5 and benzylhydrazine 6 behave as weaker activators
against both isozymes. It should be noted that the activatory effect is better emphasized when working at 0C
and with CO2 as substrate, than when working with 4-nitrophenyl acetate. This is probably due to small
differences in the catalytic mechansims involving these two substrates. In both cases the rate determining step
in catalysis is a proton transfer reaction from the zinc-bound water to the reaction medium, but presumably
when the bulkier ester is bound within the active site (together with the activator molecule), the proton
transfer process might be somehow less favoured as compared to the case in which CO2 is acting as substrate.
Isozyme on the other hand is more susceptible to activation as compared to isozyme II, probably because it
contains a smaller proportion of histidine residues as compared to HCA II, in which a cluster of such amino
acids has been recently evidenced at the entrance of the active site, and which might explain its very high
catalyticefficiency.
In fact we have recently evidenced the fact that isozymes HCA I, HCA II and BCA IV have a very
beh wour towards dffi r n
22 diverse a e e c asses of activators. It is to note that compound 5 is the first example of
activator with the general formula 1, in which a carbon atom has been substituted with one of its isosters,
i.e., an NH moiety. The obtained activator is weak indeed, similarly with phenethylamine, which also
activates around 110% at 10
.5 M.
We reported recently
23,z4 that activators of the type investigated here are non-competitive with the
substrate CO_, for BCA and HCA and II. As for the corresponding hydrase activity, also in the case of 4-
nitrophenyl acetate hydrolysis, it was recently proved that activators of the amine type bind non-
competitively to both isozymes HCA and HCA II, in agreement with the scheme proposed for explaining
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their mechanism of action (equation 3).
24’25 In order to verify the kinetic measurements mentioned above, the
electronic spectra ofthe adducts ofthese activators with Co(II)-CA were measured. It is known that the Co(II)
ion in Co(II)-CA is a good spectroscopic probe for the interaction of the enzyme with its substrates and
inhibitors.
26z8 Electronic spectra ofCo(II)-HCA II and its adducts with some activators investigated here are
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Fig. 2: Electronic spectra of Co(II)-HC;A II (continuous line) and its adducts with serotonin 3 and
benzylhydrazine 6 (uppermost spectrum). Conditions were: enzyme concentration 0.4 mM in all
experiments; activator concentrations were [serotonin]- 4.1 mM; [benzylhydrazine] 1.9 mM. pH was
maintained constant at 7.20.
From the data of Figs 2 and 3, it can be seen that slight differences appear between the spectra of the
enzyme-activator adducts, as compared to the spectrum of pure Co(II)HCA II at the same pH. These spectra
on the other hand are not similar with those of any known anionic or sulfonamide CA inhibitor.
2628 The only
spectrum to which they are similar is that of the adduct of Co(II)-CA II with phenol, the only reported
competitive inhibitor with CO2 as substrate of this isozyme.
29 This inhibitor has been shown to bind in the
hydrophobic pocket of the enzyme, without displacing the metal-bound solvent molecule. This binding has
30 been confirmed recently afterthe X-ray structure ofthe adduct has been reported by Nair et al. Phenol does
not coordinate to zinc, but binds the zinc-bound solvent through a 2.6 A hydrogen bond, and a second,
poorly oriented hydrogen bond has also been detected between the phenolic hydroxyl and the NH of Thr-199
(of 3.2 A).
The close resemblance between the electronic spectra ofour adducts with CA activators, and that of
phenol, strongly suggests that the activators investigated here bind to the enzyme in a similar manner to
phenol,
3 and to histamine
3 i.e., without displacing the zinc-bound solvent molecule. In this way, they are
able to participate in efficient proton-shuttling processes between the active site and the medium.
An exception to the above-mentioned scheme is dopamine 4. Initially, the electronic spectrum of the
adduct of this activator with CoCA II is very similar to those of adducts with histamine, serotonin,
benzylhydrazine or phenol (Fig. 3). But after 5 minutes, changes are already obvious in this spectrum. Such
changes take place for at least 45 minutes. After that time the spectrum has completely changed, being
26 28 sitnilar to that of adducts with CA inhibitors. (Fig 3).
In order to explain this phenomenon, we have redetermined activity after incubating HCA II with
dopamine for different periods (up to 24 hours), considering that initially an enzyme-activatorcomplex forms
between dopamine and CA II, in which the activator molecule binds to the metal-bound solvent, and shuttles
protons, by the general scheme explained above, but lately, another type of interaction might be favored
between the enzyme and dopamine, by which this compound directly binds to the metal ion, by means of the
two phenolic OH moieties. Such a binding has already been proposed by us for pyridinium derivatives of
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dopamine, oftype 7.
31 Such compounds were prepared in order to see whether the presence ofNH2 groups is
necessary in the molecule of a compound in order to act as CA activator.1’2 The modified derivatives 7 not
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Fig. 3" Electronic spectrum of dopamine 4 (2.4 mM) and Co(II)-HCA II (0.4 mM), in 50 mM Hepes buffer,
pH 7.60. The first spectrum in the lower part is registered at the initial time, the next one after 5 min, then
after 10 min, and the upper spectrum was obtained after 45 min.
As seen from data of Figure 4, the longer the incubation time of enzyme and dopamine, the stronger
is the activation observed. Thus, the mode of binding by means of the hydroxyl moieties may be excluded
for the zinc enzyme, but probably occurs in the case of the Co(II) derivative, taking into account the large
modifications observed in the electronic spectrum of this adduct. This is the first example in which a
compound binds differentlyto the Zn(II)-and Co(II)-containing CAs, respectively, a fact that might also
26 28 32 explain discrepancies between spectroscopic and crystallographic data of adducts of these enzymes with
anion inhibitors, which has been explained by us for the case of cyanate binding.
But activators of these widely spread enzymes, presumably possess important physiological
functions too. Of the compounds investigated by us here, at least three, histamine, serotonin and dopamine,
are important autacoids, present in concentrations high enough to elicit CA activation in many tissues.
R
ClO4"
7 R : alkyl, aryl
R
H is / ""’"
His 119
His 96
More than that, CA activation has also been reported with amino acids and oligopeptides, some of
which are important.
23 Although hypothesis have been made
a3 regarding the role of such activators in
intracellular signal-transducing systems, more detailed studies are needed in order to understand the role
played by CA activators in vivo, in physiologic as well as physiopathologic conditions, now that the
mechanism of action at molecular level ofCA activators has been probed.
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Fig. 4" Effect ofdopamine incubation with HCA II upon activation of 4-nitrophenyl acetate hydrolysis.
Conditions were: [HCA II] 0.4 M; the dopamine concentration was 0.01 mM; substrate concentration:
0.1 mM; 50 mM Tris buffer, pH 7.60, ionic strength 0.1 (K2SO4), at 25C.
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